RJFSA
NTLA icon

Raymond James Financial Services Advisors’s Intellia Therapeutics NTLA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$788K Sell
38,363
-58
-0.2% -$1.34K ﹤0.01% 2320
2024
Q2 		$860K Buy
38,421
+878
+2% +$20.9K ﹤0.01% 2183
2024
Q1 		$1.03M Buy
37,543
+1,318
+4% +$36.6K ﹤0.01% 2040
2023
Q4 		$1.1M Buy
36,225
+4,255
+13% +$122K ﹤0.01% 1921
2023
Q3 		$1.01M Buy
31,970
+5,574
+21% +$216K ﹤0.01% 1897
2023
Q2 		$1.08M Buy
26,396
+2,304
+10% +$93.4K ﹤0.01% 1886
2023
Q1 		$898K Buy
24,092
+862
+4% +$33.8K ﹤0.01% 1972
2022
Q4 		$810K Sell
23,230
-2,453
-10% -$117K ﹤0.01% 1980
2022
Q3 		$1.44M Sell
25,683
-37
-0.1% -$2.29K ﹤0.01% 1613
2022
Q2 		$1.33M Sell
25,720
-461
-2% -$23.4K ﹤0.01% 1670
2022
Q1 		$1.9M Sell
26,181
-11,649
-31% -$987K ﹤0.01% 1529
2021
Q4 		$4.47M Buy
37,830
+2,821
+8% +$353K 0.01% 1065
2021
Q3 		$4.7M Buy
35,009
+373
+1% +$56.5K 0.01% 1010
2021
Q2 		$5.61M Sell
34,636
-2,096
-6% -$163K 0.01% 913
2021
Q1 		$2.95M Buy
36,732
+12,791
+53% +$859K 0.01% 1181
2020
Q4 		$1.3M Buy
23,941
+8,408
+54% +$305K ﹤0.01% 1546
2020
Q3 		$309K Sell
15,533
-57,820
-79% -$1.21M ﹤0.01% 2262
2020
Q2 		$1.54M Buy
73,353
+62,527
+578% +$1.06M ﹤0.01% 1233
2020
Q1 		$132K Sell
10,826
-1,914
-15% -$25.8K ﹤0.01% 2183
2019
Q4 		$187K Buy
+12,740
New +$177K ﹤0.01% 2593

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial Services Advisors's NTLA Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Intellia Therapeutics (NTLA) stake by 0.15% in Q3 2024, selling an estimated $1.34K and leaving 38,363 shares worth $788K. The position accounts for ﹤0.01% of the portfolio, ranked #2320.

Raymond James Financial Services Advisors first reported a position in NTLA in Q4 2019 and has held it in 20 quarters since. The position peaked at $5.61M in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Raymond James Financial Services Advisors held 38,363 shares of Intellia Therapeutics worth $788K as of Q3 2024.
  • Raymond James Financial Services Advisors sold 58 Intellia Therapeutics shares in Q3 2024, an estimated $1.34K.
  • Intellia Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2320 holding.
  • Raymond James Financial Services Advisors first reported a position in Intellia Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • Raymond James Financial Services Advisors's Intellia Therapeutics position peaked at $5.61M in Q2 2021.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.